Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study
| Autor: | Todor Totev, Jasmina I. Ivanova, Mei Sheng Duh, Joseph H. Antin, Régis Peffault de Latour, Mehmet Bilginsoy, Lynn Huynh, Anuja Roy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Drug Resistance Kaplan-Meier Estimate Benzoates chemistry.chemical_compound 0302 clinical medicine Cost of Illness Cause of death Aged 80 and over Hematology Hematopoietic Stem Cell Transplantation Anemia Aplastic General Medicine Middle Aged Combined Modality Therapy Severe Aplastic Anemia Hydrazines 030220 oncology & carcinogenesis Cohort Health Resources Female Immunosuppressive Agents Adult Paris medicine.medical_specialty Adolescent Eltrombopag Infections Young Adult 03 medical and health sciences Chart review Internal medicine medicine Humans Blood Transfusion Aged Antilymphocyte Serum Retrospective Studies business.industry Cancer medicine.disease chemistry Sample Size Pyrazoles business Resource utilization Boston Follow-Up Studies 030215 immunology |
| Zdroj: | Annals of Hematology. 99:743-752 |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-019-03809-5 |
| Popis: | This study assessed treatment patterns and healthcare resource utilization (HRU) of patients with severe aplastic anemia (SAA) with insufficient response to immunosuppressive therapy (IST). A retrospective chart review was conducted at Dana-Farber Cancer Institute (DFCI), United States, and Hôpital Saint-Louis (HSL), France. Eligible patients were ≥ 18 years old, diagnosed with acquired SAA between January 1, 2006, and July 31, 2016, had insufficient response to IST, and had ≥ 12 months of follow-up post-diagnosis. Overall survival (OS) was estimated using the Kaplan-Meier method. Among the 40 patients, mean age at diagnosis was 44 years and 53% were women. Median follow-up time after SAA diagnosis was 48.3 months. Ninety-five percent of patients received antithymocyte globulin (ATG) as primary therapy prior to hematopoietic stem cell transplant (HSCT). Most common secondary SAA therapies prior to HSCT were eltrombopag (28%) and androgens (15%). Seventy-five percent of patients received HSCT. Prior to HSCT, patients received an average of 2.7 red blood cell (RBC) and 3.3 platelet transfusions per month; patients had 0.9 hospitalizations, 0.4 emergency room visits, and 12.8 office visits per year. Five-year OS was 75%, with infection as the primary cause of death. Additionally, this study provides information on the subgroup of patients receiving eltrombopag which was the most common secondary therapy. This study quantified transfusion and HRU burden associated with SAA and demonstrated high 5-year survival in a recently treated cohort. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink